As the foreign countries grasp what is happening with the two approved "fixes" for CV, they are going to look much harder at Leronlimab. Acceptance of this drug does not have to come from the FDA. If doctors accept it, and countries begin to use, approval will have to come from the regulatory agencies. That is a given. The market will move it to it's rightful position. We are already seeing the signs of this happening.
News 
Market Data 
Discover 
